.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Teva
Cerilliant
US Army
Express Scripts
McKesson
US Department of Justice
Dow
McKinsey

Generated: September 26, 2017

DrugPatentWatch Database Preview

Boehringer Ingelheim Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and when can generic versions of BOEHRINGER INGELHEIM drugs launch?

BOEHRINGER INGELHEIM has forty-nine approved drugs.

There are one hundred and three US patents protecting BOEHRINGER INGELHEIM drugs and there have been five Paragraph IV challenges on BOEHRINGER INGELHEIM drugs in the past three years. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

There are two thousand four hundred and sixty-nine patent family members on BOEHRINGER INGELHEIM drugs in sixty-eight countries.

Summary for Applicant: Boehringer Ingelheim

Patents:103
Tradenames:40
Ingredients:30
NDAs:49
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
COMBIPRES
chlorthalidone; clonidine hydrochloride
TABLET;ORAL017503-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-002Aug 1, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
STIOLTO RESPIMAT
olodaterol hydrochloride; tiotropium bromide
SPRAY, METERED;INHALATION206756-001May 21, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
MIRAPEX ER
pramipexole dihydrochloride
TABLET, EXTENDED RELEASE;ORAL022421-002Feb 19, 2010ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
SPIRIVA
tiotropium bromide
POWDER;INHALATION021395-001Jan 30, 2004RXYesYes► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-001Sep 24, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Boehringer Ingelheim
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL206111-002Aug 26, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
PRADAXA
dabigatran etexilate mesylate
CAPSULE;ORAL022512-002Oct 19, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
SYNJARDY XR
empagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208658-003Dec 9, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
PRADAXA
dabigatran etexilate mesylate
CAPSULE;ORAL022512-003Nov 20, 2015RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Boehringer Ingelheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
MIRAPEX
pramipexole dihydrochloride
TABLET;ORAL020667-006Feb 12, 1998► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX
pramipexole dihydrochloride
TABLET;ORAL020667-005Jul 1, 1997► Subscribe► Subscribe
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 2011► Subscribe► Subscribe
Boehringer Ingelheim
ALUPENT
metaproterenol sulfate
SOLUTION;INHALATION017659-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX ER
pramipexole dihydrochloride
TABLET, EXTENDED RELEASE;ORAL022421-004Feb 19, 2010► Subscribe► Subscribe
Boehringer Ingelheim
ALUPENT
metaproterenol sulfate
TABLET;ORAL015874-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016► Subscribe► Subscribe
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-001Sep 24, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BOEHRINGER INGELHEIM drugs

Drugname Dosage Strength Tradename Submissiondate
afatinib dimaleate
Tablets 20 mg, 30 mg and 40 mg 
GILOTRIF
7/12/2017
dabigatran etexilate mesylate
Capsuleseq. to 110 mg base
PRADAXA
12/15/2015
linagliptin
Tablets5 mg
TRADJENTA
5/4/2015
linagliptin and metformin hydrochloride
Tablets2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg
JENTADUETO
5/4/2015
dabigatran etexilate mesylate
Capsuleseq. to 75 mg base and 150 mg base
PRADAXA
10/20/2014
nevirapine
Extended-release Tablets400 mg
VIRAMUNE XR
6/21/2013
pramipexole dihydrochloride
Extended-release Tablets2.25 mg and 3.75 mg
MIRAPEX ER
7/26/2011
pramipexole dihydrochloride
Extended-release Tablets0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg
MIRAPEX ER
6/1/2010
meloxicam
Oral Suspension7.5 mg/5 mL
MOBIC
12/17/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/25 mg
MICARDIS HCT
2/27/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/12.5 mg and 40 mg/12.5 mg
MICARDIS HCT
12/31/2008
pramipexole dihydrochloride
Tablets0.75 mg
MIRAPEX
7/31/2008
aspirin and dipyridamole
Extended-release Capsules25 mg and 200 mg
AGGRENOX
2/1/2007
telmisartan
Tablets20 mg, 40 mg and 80 mg
MICARDIS
12/26/2006
pramipexole dihydrochloride
Tablets0.125 mg, 0.5 mg, 1 mg and 1.5 mg
MIRAPEX
6/24/2005
pramipexole dihydrochloride
Tablets0.25 mg
MIRAPEX
5/27/2005
tamsulosin hydrochloride
Capsules0.4 mg
FLOMAX
12/20/2004

Non-Orange Book Patents for Boehringer Ingelheim

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,499,546Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines► Subscribe
9,089,571Quinazoline derivatives for the treatment of cancer diseases► Subscribe
9,044,424Methods of regulating glucose metabolism, and reagents related thereto► Subscribe
6,169,181 Compounds useful to treat retroviral infections► Subscribe
6,682,747 Process for preparing an oral suspension of a pharmaceutical substance► Subscribe
8,404,697Quinazoline derivatives for the treatment of cancer diseases► Subscribe
6,503,440 Process for making a container with a pressure equalization opening and containers produced accordingly► Subscribe
6,121,313 Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds► Subscribe
8,377,977Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof► Subscribe
8,486,398Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Boehringer Ingelheim Drugs

Country Document Number Estimated Expiration
Brazil9507615► Subscribe
Morocco27328► Subscribe
Russian Federation2337765► Subscribe
Japan2005041885► Subscribe
Czech Republic289863► Subscribe
Australia728698► Subscribe
World Intellectual Property Organization (WIPO)2004045618► Subscribe
Estonia9900359► Subscribe
Germany19536902► Subscribe
South Korea20070052300► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
9 5009-2014Slovakia► SubscribePRODUCT NAME: OLODATEROL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 14/0394/13-S 20131029; FIRST REGISTRATION: MT MA211/00401 20130918
C/GB14/086United Kingdom► SubscribePRODUCT NAME: VILDAGLIPTIN; REGISTERED: UK EU/1/07/414/001-017 20070928
2014 00062Denmark► SubscribePRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091001
2011 00030Denmark► Subscribe
0308Netherlands► Subscribe300308, 20170424, EXPIRES: 20220423
0280Netherlands► Subscribe300280, 20170424, EXPIRES: 20220320
2014 00066Denmark► SubscribePRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130919
2012022Lithuania► SubscribePRODUCT NAME: LINAGLIPTINUM + METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/12/780/001 - EU/1/12/780/034 20120720
2014041Lithuania► SubscribePRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-024, 2007 03 21 EU/1/07/382/001-024 20070321
0216Netherlands► Subscribe300216, 20150504, EXPIRES: 20200503
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
McKesson
Harvard Business School
Cantor Fitzgerald
Colorcon
McKinsey
Citi
Deloitte
Julphar
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot